<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NALMEFENE HYDROCHLORIDE</span><br/>(nal'me-feen)<br/><span class="topboxtradename">Revex<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) antagonist</span><br/><b>Prototype: </b>Naloxone<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mcg/mL, 1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Opiate antagonist that has no opioid agonist activity; also has no pharmacologic activity when given in the absence of an
         opioid agonist.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Prevents or reverses the effects of opiates, including respiratory depression, sedation, and hypotension; these effects are
         dose related.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Complete or partial reversal of opioid drug effects, management of opioid overdose.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nalmefene.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients at high cardiovascular risk or who have received potential cardiotoxic drugs; patients with known physical dependence
         on opioids; renal or hepatic impairment; pregnancy (category B), lactation. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Reversal of Postoperative Opioid Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM/SC</span> Use 100 mcg/mL concentration, 0.25 mcg/kg followed by 0.25 mcg/kg incremental doses q25min until desired degree of reversal
               or 1 mcg/kg cumulative dose is reached<br/><br/><span class="indicationtitle">Known/Suspected Opioid Overdose</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM/SC</span> Use 1 mg/mL concentration, then for nonopioid-dependent patients: 0.5 mg/70 kg, may repeat with 1 mg/70 kg 25 min later;
               for opioid-dependent patients: 0.1 mg/70 kg, if no evidence of withdrawal in 2 min, continue with 0.5 mg/70 kg, may repeat
               with 1 mg/70 kg 25 min later (doses &gt;1.5 mg/70 kg not likely to be more effective)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: When using the 100 mcg/mL concentration, calculate the volume of a dose equal to 0.25 mcg/kg by multiplying the weight in
            kilograms by 0.0025. When using the 1 mg/mL concentration, calculate the volume of a dose equal to 0.1, 0.5, or 1 mg/70 kg
            by dividing the weight in kilograms by 70, then multiplying that result by the number of milligrams ordered per 70 kg. 			
         </li>
</ul><span class="adminroutetype">Intramuscular/</span><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li> 				Note: If IV access is lost, a single 1-mg dose may be given IM or SC. Allow 515 min for effect to occur. 			</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 1530 sec. In patients with kidney failure give over 60 sec.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fever, chills. <span class="typehead">CV:</span> Tachycardia, hypotension, hypertension, pulmonary edema, ventricular arrhythmias (especially in patients with preexisting
      cardiovascular disease). <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting,</span> diarrhea, dry mouth, dyspepsia, elevation of liver function tests. <span class="typehead"> CNS:</span> Dizziness, headache, irritability, tremor, paresthesias, confusion, paranoia, drowsiness, fatigue, vertigo, agitation, nervousness. <span class="typehead">Special Senses:</span> Blurred vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Potential risk of seizures when combined with <b>flumazenil.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from IM and SC sites. <span class="typehead">Onset:</span> 25 min IV; 15 min IM/SC. <span class="typehead">Peak:</span> 5 min IV; 2 h IM/SC. <span class="typehead">Duration:</span> 48 h. <span class="typehead">Distribution:</span> Approximately 45% protein bound; blocks &gt;80% of brain opioid receptors within 5 min; distributed into breast milk
      of rats. <span class="typehead">Metabolism:</span> Metabolized in liver by glucuronidation. <span class="typehead">Elimination:</span> Metabolites excreted primarily in urine, 17% excreted in feces. <span class="typehead">Half-Life:</span> 8.510.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for reversal of opioid depression within 25 min of an IV dose or 515 min of an IM/SC dose.</li>
<li> 							Note: If recurrent respiratory depression following the reversal, titrate the dose again to avoid over-reversal. 						</li>
<li>Monitor cardiovascular status closely, assessing for changes in blood pressure and heart rate and development of arrhythmias.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>